The emerging strategy of comprehensive therapy for esophageal cancer: immunotherapy

被引：0
作者：
Wang, Yuandong [1 ]
Tang, Xinyu [1 ]
Min, Hua [1 ]
Zhu, Hongcheng [1 ]
Lu, Qian [1 ]
Zhang, Shu [1 ]
Sun, Xinchen [1 ]
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, 300 Guanzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
来源：
TRANSLATIONAL CANCER RESEARCH | 2016年 / 5卷 / 06期
关键词：
Esophageal cancer (EC); tumor immunology; immunotherapy; T-CELLS; NY-ESO-1; PROTEIN; UNITED-STATES; CARCINOMA; SURVIVAL; CHEMORADIOTHERAPY; TRENDS; LOCALIZATION; CHEMOTHERAPY; METAANALYSIS;
D O I：
10.21037/tcr.2016.12.04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Esophageal cancer (EC) is a highly malignant tumor, and the overall survival rate remains very low. Traditional treatment is not sufficiently effective, and thus, there is an urgent need for new and effective treatments. The advances in cancer immunotherapy have changed this situation because this type of therapy has a significant potential to eliminate tumors with little damage to normal tissue. This treatment primarily aims to enhance the ability of the immune system to eliminate tumors and prevent tumor immune escape, which is associated with immune surveillance. This review summarizes current cancer therapeutic strategies and immunotherapy studies to demonstrate the potential of immunotherapy for the treatment of EC.
引用
收藏
页码：871 / 876
页数：6
相关论文
共 38 条
  • [1] Compensatory anti-inflammatory response syndrome
    Adib-Conquy, Minou
    Cavaillon, Jean-Marc
    [J]. THROMBOSIS AND HAEMOSTASIS, 2009, 101 (01) : 36 - 47
  • [2] Hospital volume and surgical mortality in the United States.
    Birkmeyer, JD
    Siewers, AE
    Finlayson, EVA
    Stukel, TA
    Lucas, FL
    Batista, I
    Welch, HG
    Wennberg, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) : 1128 - 1137
  • [3] Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
    Calabro, Luana
    Morra, Aldo
    Fonsatti, Ester
    Cutaia, Ornella
    Amato, Giovanni
    Giannarelli, Diana
    Di Giacomo, Anna Maria
    Danielli, Riccardo
    Altomonte, Maresa
    Mutti, Luciano
    Maio, Michele
    [J]. LANCET ONCOLOGY, 2013, 14 (11) : 1104 - 1111
  • [4] Conforti AM, 1997, J SURG ONCOL, V66, P55, DOI 10.1002/(SICI)1096-9098(199709)66:1<55::AID-JSO12>3.0.CO
  • [5] 2-N
  • [6] The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?
    Crehange, Gilles
    Conroy, Thierry
    [J]. JOURNAL OF THORACIC DISEASE, 2016, 8 (06)
  • [7] Historical insights into cytokines
    Dinarello, Charles A.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 : S34 - S45
  • [8] Immune Regulation of Cancer
    Disis, Mary L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4531 - 4538
  • [9] Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis
    Fan, Mengying
    Lin, Yao
    Pan, Jianhong
    Yan, Wanpu
    Dai, Liang
    Shen, Luyan
    Chen, Keneng
    [J]. THORACIC CANCER, 2016, 7 (02) : 173 - 181
  • [10] Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development
    Forghanifard, Mohammad Mahdi
    Gholamin, Mehran
    Moaven, Omeed
    Farshchian, Moein
    Ghahraman, Martha
    Aledavood, Amir
    Abbaszadegan, Mohammad Reza
    [J]. MEDICAL ONCOLOGY, 2014, 31 (10)
1234